GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Cepheid (CPHD) [hlAlert]

Rating:
Buy CPHD
up 43.15 %

Cepheid (CPHD) upgraded to Buy with price target $44 by Needham

Posted on: Thursday,  Dec 17, 2015  8:25 AM ET by Needham

Needham rated Buy Cepheid (NASDAQ: CPHD) on 12/17/2015, when the stock price was $34.46. Since then,
Cepheid has gained 43.15% as of 01/07/2016's recent price of $49.33.
If you would have followed this Needham's recommendation on CPHD, you would have gained 43.15% of your investment in 21 days.

Cepheid, Inc. develops, manufactures and markets microfluidic systems that integrate, automate and accelerate biological testing. Their systems are miniaturized instruments that analyze complex biological samples in a disposable cartridge by combining molecular biology with microfluidic technology that processes small quantities of liquid, typically using components fabricated with computer chip technology. These systems rapidly perform all of the steps required to analyze complex biological samples.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/17/2015 8:25 AM Buy
None
34.46 44.00
as of 12/13/2013
1 Week down  -4.63 %
1 Month up  4.81 %
3 Months up  15.82 %
1 YTD up  30.53 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/21/2015 8:25 AM Hold
None
30.64
10/14/2015 8:25 AM Buy
None
33.52 47.00
5/27/2014 12:00 AM Buy
None
50.00
12/19/2013 8:25 AM Hold
None
46.67
10/14/2009 8:25 AM Buy
None
13.86 17.00
1/9/2009 9:25 AM Hold
None
9.13
11/20/2008 8:25 AM Buy
None
12.14 21.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy